LONDON, September 5, 2014 /PRNewswire/ --
Clinical Microbiology and Infection and New Microbes & New Infections to be published by Elsevier effective January 2015
Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, announced today that an agreement has been reached with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) to publish its flagship journals, Clinical Microbiology and Infection (CMI) and New Microbes & New Infections (NMNI) beginning January 1, 2015.
"Elsevier and ESCMID have collaborated on a number of projects over the years and we are delighted to strengthen our relationship as ESCMID's publishing partner for CMI and NMNI," commented Anne Kitson, Executive Vice President, Health and Medical Sciences Journals at Elsevier. "We look forward to working with ESCMID to ensure the continuing success of CMI and to support the editorial team of NMNI as they forge a new, exciting path within the community."
Established in 1995, CMI is widely recognized as one of the premier international journals in the field. It is guided by an eminent editorial board led by Editor-in-Chief Didier Raoult, MD, PhD, Aix-Marseille University, Marseille, France. The journal publishes peer-reviewed papers that present basic and applied research relevant to therapy and diagnostics in the fields of microbiology, infectious diseases, virology, parasitology, immunology and epidemiology.
To allow quick publication of new events in clinical microbiology and to facilitate data sharing by scientists in the field across the globe, ESCMID launched NMNI in 2013 under the leadership of Editor-in-Chief Michel Drancourt, MD, PhD, Aix-Marseille University. It serves the field as a multilingual, peer-reviewed, open access journal for rapid dissemination of the latest research, with a particular focus on new genomes, new microbes and new technology applied to the diagnosis of infectious and tropical diseases.
Murat Akova, MD, ESCMID President, remarked, "The Society is extremely pleased to enter into this new phase of our relationship with Elsevier. It will enable us to expand the impact and global reach of our publications, which are key information resources in the professional lives of microbiologists and infectious disease specialists."
ESCMID is a non-profit organization dedicated to improving the diagnosis, treatment and prevention of infectious diseases in Europe and beyond. The Society promotes and supports research, education and training in clinical microbiology and infectious diseases and shares good medical practice in both disciplines to build capacity throughout Europe. http://www.escmid.org
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).